Rigvir Holding

Our vision is to be a global, best-in-class immuno-oncology company that creates impactful drugs for patients with the highest medical needs. Founded in Canada in 2015, Virogin aims to unleash synergy between oncolytic virotherapy and mRNA vaccines in the battle against cancer. We have developed two platforms: (1) innovative HSV-1 based oncolytic virus and (2) mRNA-based (including self-amplifying RNA/saRNA) therapeutics, aiming to elicit robust and durable anti-tumor immune response against solid tumors.

ViraTherapeutics is a distinct unit of the Discovery Research organization of the Boehringer Ingelheim group of companies. ViraTherapeutics specializes in the development of highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. ViraTherapeutics develops a new class of immunotherapy drugs based on oncolytic (cancer-destroying) viruses. ViraTherapeutics currently performs preclinical safety and efficacy studies for our modified Vesicular Stomatitis Virus (VSV-GP) and aims to conduct first clinical trials in cancer patients in the near future. We are committed to developing new treatments for people living with cancer and improving their quality of life. Take your chance and check our recent job offers.

At Vyriad, we are developing the next generation of targeted cancer therapies using engineered viruses that selectively attack cancer cells and ignite robust immune responses to prevent cancer recurrence. Vyriad has developed proprietary technology to rapidly engineer VSV to boost its anticancer activity, and to allow noninvasive monitoring in patients. At Vyriad, we are relentlessly curious and singularly dedicated to turning viruses into effective anticancer drugs for cancer patients. Vyriad is based in Rochester, Minnesota, ranked 9th in the 2018 Top 100 Best Places to Live and home to Mayo Clinic, the nation’s best hospital. We are expanding our R&D, clinical operations and GMP manufacturing teams to support the ambitious goals of our company. We believe our oncolytic viruses have tremendous potential to improve the lives of patients, inspire hope and change the way cancer is treated. Vesicular Stomatitis Virus (VSV) is a potent, rapidly replicating virus with the ability to target, infect and kill cancer cells after intravenous delivery. Measles is a fusogenic virus that utilizes diverse cancer killing mechanisms which may trigger robust anti-cancer immune activity.

Our vision: Affordable, best-in-class cancer treatments with fewer side effects for an improved quality-of-life under treatment. CanVirex is a spin-off from the Heidelberg University Hospital, founded in 2017 in Basel, Switzerland. CanVirex and Heidelberg University Hospital have signed a strategic collaboration agreement for the research and clinical development of measles-vectored therapeutics. CanVirex has also forged strategic collaborations with key industry partners for GMP manufacturing and commercialization of our products. CanVirex’s measles vector-based platform represents a highly promising technology for cancer immunotherapy and vaccine development against infectious diseases. CanVirex AG operates out of its headquarter in Basel, Switzerland. The Heidelberg University Hospital offers a unique infrastructure for swift clinical translation of our most promising drug candidates. The translational program, supported by CanVirex, routinizes testing of molecular signatures and predictive biomarkers.

ImmVirX seeks to advance a new generation of cancer treatments by developing a novel oncolytic immunotherapy that targets cancer indications with high unmet need. ImmVirX was founded in late 2019 by the team from Viralytics, a clinical-stage ASX-listed oncolytic virus company acquired in June 2018 by Merck and Co. We are developing proprietary bio-selected RNA viruses with the capacity to selectively infect and kill cancer cells while also inducing tumour inflammation and achieving immune cell infiltration – potentially leading to the generation of specific innate and adaptive immune responses against cancer cells.Our viral candidates are intended to increase the anti-tumour activity of current cancer immunotherapies, including immune checkpoint inhibitors, CAR-Ts and other cell therapies, and are targeted against a range of difficult-to-treat cancers, including colorectal, gastric, hepatocellular and ovarian cancer. The ImmVirX team comprises key directors, executives and scientific staff from Viralytics. ImmVirX is a clinical stage oncology company developing novel oncolytic viruses to create powerful cancer immunotherapy combinations. ImmVirX is pleased to advise that Co-Founder and CEO Dr Malcolm McColl’s presentation at The @Bell_Potter Healthcare Conference 2023 is now available. Our team is based in state-of-the-art R&D facilities at the Hunter Medical Research Institute (HMRI) and is supported by the University of Newcastle Research Associates (TUNRA) in Newcastle, New South Wales, Australia. Leveraging our leadership and experience in oncolytic viral therapies, we are actively progressing clinical trials, based on a body of pre-clinical and manufacturing data developed since operations commenced in 2020.

RetroVirox is an innovative, privately-held CRO and biotechnology company dedicated to discovering new treatments for patients with infectious diseases. RetroVirox offers antiviral testing and customized early stage discovery solutions to other Life Sciences companies working in the antiviral and infectious disease diagnostics field. RetroVirox provides different opportunities to fulfill the needs of these companies, offering a broad menu of antiviral assays in a fee-for-service or F.T.E. RetroVirox is also developing small-molecules for the treatment of viral diseases and cancer. RetroVirox was founded with an initial investment by scientists and entrepreneurs to translate early-stage research into cures. The company offers its discovery platforms and antiviral services to other Biotechnology and Pharmaceutical companies.